Mass spectrometric approaches to assess the biodistribution and fate of cationic surfactants used as drug delivery nanoparticles

质谱方法评估用作药物递送纳米粒子的阳离子表面活性剂的生物分布和归宿

• 批准号: RGPIN-2015-03715
• 负责人: ElAneed, Anas
• 金额: $ 1.46万
• 依托单位: University of Saskatchewan
• 依托单位国家: 加拿大
• 项目类别: Discovery Grants Program - Individual
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=632606
• 关键词: Mass; spectrometric; approaches; assess; biodistribution

In the pharmaceutical industry, the fastest growing area is drug delivery, accounting currently for more than $80 billion of total value, including gene delivery. The latter has gained momentum with the recent first approval in the European Union of the gene therapy, Glybera® for the treatment of genetic lipid disorders. In fact, there are 5000 genetic diseases that do not have a cure. Therefore, it is not surprising that over 2000 clinical trials (i.e. human testing) have been conducted, evaluating various gene therapy strategies.

在制药行业中，生长最快的地区是药物输送，目前的总价值超过800亿美元，包括基因交付。随着欧洲基因疗法联盟Glybera®的最新批准，后者已经获得了动力，用于治疗遗传脂质疾病。实际上，有5000种无法治愈的遗传疾病。因此，已经进行了2000多个临床试验（即人类测试），评估各种基因治疗策略，这并不奇怪。